NO20082833L - Farmasoytiske preparater - Google Patents

Farmasoytiske preparater

Info

Publication number
NO20082833L
NO20082833L NO20082833A NO20082833A NO20082833L NO 20082833 L NO20082833 L NO 20082833L NO 20082833 A NO20082833 A NO 20082833A NO 20082833 A NO20082833 A NO 20082833A NO 20082833 L NO20082833 L NO 20082833L
Authority
NO
Norway
Prior art keywords
pharmaceutical preparations
opioids
otic
cats
dogs
Prior art date
Application number
NO20082833A
Other languages
English (en)
Inventor
Robert D Simmons
Allan Weingarten
Yuping Li
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37745944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20082833(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of NO20082833L publication Critical patent/NO20082833L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Metode for tilveiebringelse av systemisk analgesi til katter, hunder og andre smådyr ved otisk eller transdermal administrering av opioider er beskrevet. Preparatene for anvendelse i en slik metode er også beskrevet.
NO20082833A 2005-11-21 2008-06-20 Farmasoytiske preparater NO20082833L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73852405P 2005-11-21 2005-11-21
PCT/US2006/044464 WO2007061739A2 (en) 2005-11-21 2006-11-16 Pharmaceutical compositions comprising buprenorphine

Publications (1)

Publication Number Publication Date
NO20082833L true NO20082833L (no) 2008-07-29

Family

ID=37745944

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082833A NO20082833L (no) 2005-11-21 2008-06-20 Farmasoytiske preparater

Country Status (17)

Country Link
US (2) US20070117828A1 (no)
EP (2) EP1951240A2 (no)
JP (2) JP2009516686A (no)
KR (1) KR20080071185A (no)
CN (1) CN101312730A (no)
AR (1) AR058193A1 (no)
AU (1) AU2006316607A1 (no)
BR (1) BRPI0618891A2 (no)
CA (2) CA2630072A1 (no)
EC (1) ECSP088461A (no)
NO (1) NO20082833L (no)
NZ (1) NZ568313A (no)
PE (1) PE20070643A1 (no)
RU (1) RU2008124805A (no)
TW (1) TW200738240A (no)
WO (2) WO2007061739A2 (no)
ZA (2) ZA200804305B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2522343A1 (en) 2006-03-28 2012-11-14 Javelin Pharmaceuticals, Inc. Formulations of Low Dose Diclofenac and Beta-Cyclodextrin
MX2008012496A (es) * 2006-03-28 2009-01-07 Javelin Pharmaceuticals Inc Formulaciones de farmacos anti-inflamatorios no esteroidales de baja dosis y beta-ciclodextrina.
GB2461681A (en) * 2008-04-17 2010-01-13 Pharmasol Ltd Buprenorphine liquid spray formulation with solvent and antioxidant
PE20081406A1 (es) * 2006-12-20 2008-10-17 Schering Plough Ltd Composiciones farmaceuticas de flunixina
BRPI0818483A2 (pt) * 2007-11-01 2015-04-14 Bausch & Lomb Método para preparar uma composição farmacêutica, composição farmacêutica, e, uso da mesma.
CA2728727C (en) * 2008-06-24 2018-01-23 Intervet International B.V. Pharmaceutical transdermal compositions and method for treating inflammation in cattle
WO2010072398A2 (en) 2008-12-22 2010-07-01 Boehringer Ingelheim Limited Veterinary formulations
WO2011049958A2 (en) * 2009-10-21 2011-04-28 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
JP5956992B2 (ja) * 2010-08-17 2016-07-27 オーエイチアール・ファーマシューティカル・インコーポレイテッドＯｈｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌ，Ｉｎｃ． スクアラミンの眼用製剤
US9168251B2 (en) * 2010-09-03 2015-10-27 Zoetis Belgium S.A High dose buprenorphine compositions and use as analgesic
EP3363439B1 (en) * 2010-10-25 2025-01-08 University Of Manitoba Therapeutic compositions for diabetic symmetrical polyneuropathy
WO2013070656A1 (en) * 2011-11-07 2013-05-16 Navinta Llc Sustained release suspension preparation for dextromethorphan
US9962391B2 (en) 2011-12-27 2018-05-08 Cmpd Licensing, Llc Composition and method for compounded therapy
US9468599B2 (en) 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213500B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
US10813897B2 (en) 2011-12-27 2020-10-27 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213501B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
WO2014160702A1 (en) * 2013-03-25 2014-10-02 Chs Pharma, Inc. Retinopathy treatment
CA2908583A1 (en) * 2013-04-08 2014-10-16 Virginia Commonwealth University Compositions to alleviate presystemic metabolism of opioids
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US20160128997A1 (en) 2014-11-07 2016-05-12 Indivior Uk Limited Sustained-release buprenorphine formulations
JP2018531964A (ja) * 2015-10-27 2018-11-01 インシス・ディベロップメント・カンパニー・インコーポレイテッド 液体ブプレノルフィン製剤
PL3512518T3 (pl) * 2016-09-13 2023-03-27 Alar Pharmaceuticals Inc. Preparaty buprenorfiny o przedłużonym uwalnianiu
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
GB201716830D0 (en) 2017-10-13 2017-11-29 Cambrex Charles City Inc New Process
MA50394A (fr) 2017-10-20 2021-04-28 Chiesi Farm Spa Formulations pharmaceutiques comprenant un agoniste de récepteur d'opioïde en tant que substances actives, leurs procédés de fabrication et leurs utilisations thérapeutiques
WO2019144079A1 (en) * 2018-01-22 2019-07-25 Yuhua Li Pharmaceutical composition for sustained release delivery of buprenorphine
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
JP2024536239A (ja) * 2021-09-30 2024-10-04 エランコ・ユーエス・インコーポレイテッド ブプレノルフィンの安定な製剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8533582A (en) * 1981-07-10 1984-01-12 Reckitt & Colman Products Limited Stable solutions of buprenorphine
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4931279A (en) * 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US6384043B1 (en) * 1993-02-01 2002-05-07 Gholam A. Peyman Methods of alleviating pain sensations of the denuded eye with opioid analgesics
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5871723A (en) * 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
ATE218328T1 (de) * 1996-03-25 2002-06-15 Lohmann Therapie Syst Lts Transdermales therapeutisches system mit geringer applikationsdicke und hoher flexibilität sowie herstellungsverfahren
US6004969A (en) * 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
IT1302682B1 (it) * 1998-10-16 2000-09-29 Formenti Farmaceutici Spa Composizioni farmaceutiche orali contenenti buprenorfina
KR100383252B1 (ko) * 1998-12-17 2003-07-16 주식회사 삼양사 부프레놀핀을함유하는경피투여조성물및이를포함하는패취
AU5170400A (en) * 1999-05-27 2000-12-18 George F. El Khoury Topical application of muscarinic and opioid agents for treatment of tinnitus
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
KR100452972B1 (ko) * 2000-05-16 2004-10-14 주식회사 삼양사 경피투여용 하이드로젤 조성물
CA2386794A1 (en) * 2000-07-13 2002-01-24 Euro-Celtique, S.A. Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics
US20040258740A1 (en) * 2003-04-10 2004-12-23 Nene Labs Transdermal delivery composition

Also Published As

Publication number Publication date
BRPI0618891A2 (pt) 2011-09-13
WO2007061828A2 (en) 2007-05-31
EP1951240A2 (en) 2008-08-06
AU2006316607A1 (en) 2007-05-31
JP2009516687A (ja) 2009-04-23
ZA200804355B (en) 2009-04-29
WO2007061739A2 (en) 2007-05-31
WO2007061739A3 (en) 2007-07-12
ZA200804305B (en) 2009-04-29
WO2007061828A3 (en) 2007-07-19
KR20080071185A (ko) 2008-08-01
US20070117828A1 (en) 2007-05-24
CA2630072A1 (en) 2007-05-31
TW200738240A (en) 2007-10-16
NZ568313A (en) 2011-11-25
ECSP088461A (es) 2008-06-30
PE20070643A1 (es) 2007-08-10
CA2629560A1 (en) 2007-05-31
CN101312730A (zh) 2008-11-26
JP2009516686A (ja) 2009-04-23
US20070116730A1 (en) 2007-05-24
EP1954275A2 (en) 2008-08-13
AR058193A1 (es) 2008-01-23
RU2008124805A (ru) 2009-12-27

Similar Documents

Publication Publication Date Title
TW200738240A (en) Pharmaceutical compositions
NO20080068L (no) Topisk unguale formuleringer
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
CL2007001453A1 (es) Metodo para enviar comunicacion de inter-proximidad en un arbol de anillos en un sistema de computador facilitando la comunicacion de una federacion rendezvous.
BRPI0519391A2 (pt) mÉtodo para promover a saéde oral em um animal, kit adequado para administraÇço de um ou mais antioxidantes a um animal, dispositivo para transmitir informaÇço ou instruÇÕes, e, uso de uma composiÇço
ECSP10010684A (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad.
NO20090305L (no) Cyklosporin formuleringer
CR11472A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
IL195748A0 (en) Benzimidazole derivatives, method for the production thereof, their use as fxr agonists and pharmaceutical preparations containing the same
BR112013002112A2 (pt) composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável ou n-óxido, ou um solvato ou hidrato do mesmo, ou de uma composição
CL2011001131A1 (es) Uso de una formulacion que sirve para preparar un medicamento para una inyeccion, que reduce al minimo la inflamacion en el sitio de la inyeccion de un anticuerpo, y donde la formulacion comprendeun anticuerpo 2h7 y variantes del anticuerpo y polivinilpirrolidona (pvp)
WO2007070052A3 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
BRPI0510909A2 (pt) composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
CL2009000882A1 (es) Un compuesto n-(4-cloro-3-(piridin-2-il)fenil)-4-(2-hidroxi-2-metilpropilsulfonil)-2-metilbenzamida, inhibidor de la via de señalización hedgehog; composición farmacéutica que comprende a dicho compuesto; y su uso para tratar el cancer.
CL2007003726A1 (es) Anticuerpos anti-receptor del factor del crecimiento similar a la insulina i (igf-ir); composicion farmaceutica que lo contiene; y su uso para tratar el cancer.
EA201170772A1 (ru) Органические соединения
BR112016007408A2 (pt) inibidores de metalo-beta-lactamase (mbl) compreendendo uma porção de quelação de zinco
CL2011000206A1 (es) Composicion biocida que comprende ciprodinil y fluazinam; metodo para controlar enfermedades, en plantas utiles o en material de propagacion, causadas por fitopatogenos (div. sol. n°2602-06).
MX275245B (es) Composicion de acaros, uso de la misma, metodo para criar un acaro predatorio phytoseiid, sistema de crianza para criar dicho acaro predatorio phytoseiid y metodos para el control biologico de plagas en un cultivo.
AR074471A1 (es) Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer
BRPI0811534A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticametne aceitável do mesmo.
CL2011000135A1 (es) Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.
AR064254A1 (es) Maiz extraido con solvente
DE602007004262D1 (de) Erstellung von Substrings unter Wahrung der Privatsphäre
EA200702594A1 (ru) Многофункциональные композиции концентрата с высоким содержанием действующего вещества для контроля эктопаразитов

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application